Your browser doesn't support javascript.
loading
The relevance between anti-rods/rings antibody and different treatment regimens in chronic hepatitis C virus infection.
Peker, Bilal Olcay; Sener, Asli Gamze; Topal, Firdevs; Saritas Yüksel, Elif.
Afiliação
  • Peker BO; Department of Medical Microbiology, Izmir Katip Çelebi University Atatürk Training And Research Hospital, Izmir, Turkey.
  • Sener AG; Department of Medical Microbiology, Izmir Katip Çelebi University Atatürk Training And Research Hospital, Izmir, Turkey.
  • Topal F; Department of Gastroenterology, Izmir Katip Çelebi University Medical Faculty, Izmir, Turkey.
  • Saritas Yüksel E; Department of Gastroenterology, Izmir Katip Çelebi University Medical Faculty, Izmir, Turkey.
Microbiol Immunol ; 65(4): 171-177, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33538354
ABSTRACT
The antibodies and other issues associated with immunity in chronic hepatitis C virus (HCV) have been widely investigated, especially non-organ-specific antinuclear antibodies. Rods-rings (RR) antibody patterns are frequently observed due to pegylated IFN-α (PEG-IFN)/ribavirin (RBV) treatment by indirect immunofluorescence (IIF). We evaluated the relevance between anti-RR and PEG-IFN/RBV and/or direct-acting antiviral (DAA) regimens in chronic HCV. Sampling was done after achieving a sustained virological response (SVR) for 178 patients (aged >18 years). Patients were grouped according to treatment protocols (Group 1 [G1] PEG-IFN/RBV [n = 53], Group 2 [G2] PEG-IFN/RBV and Telaprevir or Boceprevir [n = 31], Group 3 [G3] second- and third-wave DAA and previously received PEG-IFN/RBV (n = 38), and Group 4 [G4] second- and third-wave DAA [n = 56]). Anti-RR was investigated by IIF (Euroimmun AG) test. Overall, 27 (15.16%) patients were anti-RR positive and received PEG-IFN/RBV. The numbers of anti-RR positivity for G1/2/3/4 (%) were 16/3/8/0 (30.2/9.6/21/0), respectively (p < .001). The anti-RR positivity rate for G1/2/3 was 22.13% (27/122, p = .088). Anti-RR was positive in 17.5% (11/63) of G1/2/3 patients who did not achieve SVR after the first treatment. This rate was 27.1% (16/59) in patients with SVR after the first treatment in G1/2 and there was no difference between these two classified groups in terms of antibody titers (p = .915). Anti-RR was detected up to 172 months after SVR. In summary, anti-RR was positive in high rates in patients receiving PEG-IFN/RBV therapy. Frequent monitoring is needed during patient follow-up to get more data on the relationship between anti-RR titer, treatment regimens, and SVR.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Anticorpos Anti-Hepatite / Anticorpos Antinucleares / Hepatite C Crônica Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Microbiol Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Anticorpos Anti-Hepatite / Anticorpos Antinucleares / Hepatite C Crônica Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Microbiol Immunol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia